Orbimed Advisors LLC Bio Atla, Inc. Transaction History

Orbimed Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $249,723 - $450,970	-146,896 Reduced 12.71%	1,009,279 $1.72 Million
Q2 2023 Aug 14, 2023	SELL	$2.83 - $3.87 $7.65 Million - $10.5 Million	-2,704,825 Reduced 70.06%	1,156,175 $3.47 Million
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $8.12 Million - $29.1 Million	3,528,628 Added 1061.65%	3,861,000 $10.3 Million
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $2.09 Million - $3.66 Million	332,372 New	332,372 $2.74 Million

17.4M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $16.3M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.